OPC-64005 / Otsuka - LARVOL DELTA

A Phase 2 Trial of OPC-64005 for Major Depressive Disorder (clinicaltrials.gov) - P2 | N=273 | Completed | Sponsor: Otsuka Pharmaceutical Co., Ltd. | Recruiting ➔ Completed

Trial completion • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Phase 2 Trial of OPC-64005 for Major Depressive Disorder (clinicaltrials.gov) - P2; N=270; Recruiting; Sponsor: Otsuka Pharmaceutical Co., Ltd.; Trial completion date: Nov 2021 ➔ Feb 2022; Trial primary completion date: Nov 2021 ➔ Feb 2022

Clinical • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Beyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD. (PubMed, Expert Rev Neurother) - "Expert opinion: The authors found 28 pertinent RCTs of compounds acting on a variety of biological targets, including Dasotraline, Viloxazine (SPN-812), Centanafadine SR (CTN SR), OPC-64005, Fasoracetam (NFC-1, AEVI-001), Metadoxine (MDX), Vortioxetine, Tipepidine Hibenzate, Oxytocin, Sativex (delta-9-tetrahydrocannabinol (THC) plus cannabidiol), Mazindol, and Molindone hydrochloride (SPN-810)...However, they may offer comparable or better tolerability. Additionally, agents acting on etiopathophysiological targets disrupted in specific subgroups of patients with ADHD will move forward the pharmacotherapy of ADHD from a "one size fits all" to a "precision medicine" approach."

Clinical • Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

A Phase 2 Trial of OPC-64005 for Major Depressive Disorder (clinicaltrials.gov) - P2; N=270; Recruiting; Sponsor: Otsuka Pharmaceutical Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

A Phase 2 Trial of OPC-64005 for Major Depressive Disorder (clinicaltrials.gov) - P2; N=270; Not yet recruiting; Sponsor: Otsuka Pharmaceutical Co., Ltd.

New P2 trial